Eko announced today that it launched its newly redesigned Eko application that aids in screening for cardiovascular disease.
Oakland, California–based Eko develops smart stethoscopes to pair with its accompanying automated disease detection software with the Eko app for analyzing heart sounds with FDA-cleared artificial intelligence (AI)-powered algorithms.
According to a news release, Eko aims to utilize the newly redesigned app to transform patient interactions into an opportunity to screen for cardiovascular disease, with the AI algorithms capable of detecting heart murmurs and AFib within seconds.
Eko said it had the AI algorithm clinically validated to perform at a sensitivity of 87.6% and specificity of 87.8% in identifying heart murmurs. In addition, Eko’s AFib algorithm produced a sensitivity of 98.9% and specificity of 96.9%.
Dr. Joanna Kmiecik, a family medicine specialist in Chicago, said in the news release that Eko’s products offer ease of use and portability. The result is that Kmiecik can examine patients in the office with minimal impact on her physical examination routine. She added that patients even “enjoy how they can engage with the app.”
“Frontline healthcare professionals are our best line of defense in catching cardiovascular disease early on, but they are challenged to do so by outdated tools, insufficient time, and inadequate resources,” said Connor Landgraf, Eko’s CEO and co-founder. “With a disease that is so pervasive in our society, it is imperative that we provide every healthcare professional with a solution that helps them diagnose with more confidence and give their patients the best care possible. This is how we’ll save millions of lives in the coming years.”